Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Paradigm Co-founder Matt Huang Appointed as the First CEO of Stripe’s Blockchain Project Tempo

Paradigm Co-founder Matt Huang Appointed as the First CEO of Stripe’s Blockchain Project Tempo

金色财经金色财经2025/08/12 22:46
Show original

According to several sources familiar with the matter, Jinse Finance reports that payment giant Stripe has appointed Matt Huang, co-founder and managing partner of crypto venture capital firm Paradigm, as the first CEO of its new blockchain initiative, Tempo, which is accelerating Stripe’s entry into the blockchain sector. Huang is also a member of Stripe’s board of directors and will continue to serve as managing partner at Paradigm. Previous reports indicated that Stripe is collaborating with Paradigm to develop the L1 blockchain Tempo.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11